Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma

查看全文 作　　者：Naoshi [1]Nishida

机构地区：[1]Department of Gastroenterology and Hepatology,Kindai University Faculty of Medicine,Osaka,Japan

出　　处：《Hepatobiliary Surgery and Nutrition》索引2020年第9卷第5期,共4页

摘　　要：Currently,liver cancer is the fourth most common cause of cancer mortality worldwide.The overwhelming majority of liver cancers are hepatocellular carcinomas(HCC),developing on the background of chronic liver diseases,including chronic hepatitis B,chronic hepatitis C,and non-alcoholic steatohepatitis(1).Despite the recent progress in the treatment of HCC,it remains largely refractory,with a high recurrence rate even after therapeutic intervention(2).Numerous agents,including tyrosine-kinase inhibitors(TKIs),antibodies blocking the vascular endothelial growth factor(VEGF)/VEGF receptor(VEGFR)axis,and immune checkpoint inhibitors,are now available for the treatment of advanced stage HCC(3).However,their antitumor responses are still unsatisfactory. 关键词：HEPATOCELLULAR MORTALITY TREATMENT

相关文献

参考文献（15）
引证文献（3）
耦合文献（4）

参考文献(15)

引证文献(3)

耦合文献(4)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma

参考文献(15)

引证文献(3)

耦合文献(4)

用户提示